DSM invests in biomaterials company Oxford Performance Materials
Advertisement
DSM Venturing, the corporate venturing unit of Royal DSM N.V., announced that it has invested $ 1.2 mln in the biomaterials company Oxford Performance Materials (OPM). This investment links on to DSM's innovation ambitions in the emerging business area (EBA) of biomedical materials, which is an important element of DSM's strategy Vision 2010 - Building on Strengths.
OPM markets biocompatible high performance polymers for use in medical device applications such as catheters and implantable devices. OPM's polymers offer advantages over metals in terms of improved biocompatibility, process flexibility, radiolucense and tailored formulations to meet biomechanical and design criteria.